Gastroenterology (AGA) published a clinical update in Research Highlights on 23 Mar 2026. The item focuses on Efimosfermin, a fibroblast growth factor 21 analogue, for metabolic dysfunction-associated steatohepatitis. Review the original article for the full source wording and details.
Gastroenterology (AGA) published a clinical update in Research Highlights on 23 Mar 2026.
The item focuses on Efimosfermin, a fibroblast growth factor 21 analogue, for metabolic dysfunction-associated steatohepatitis.
Review the original article for the full source wording and details.